New Risk • May 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (₹2.13b market cap, or US$22.5m). Valuation Update With 7 Day Price Move • May 01
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹152, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past year. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹127, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.5% over the past year. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹110, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 12% over the past year. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹2.46 (vs ₹1.70 in 3Q 2025) Third quarter 2026 results: EPS: ₹2.46 (up from ₹1.70 in 3Q 2025). Revenue: ₹311.8m (up 1.7% from 3Q 2025). Net income: ₹40.3m (up 45% from 3Q 2025). Profit margin: 13% (up from 9.1% in 3Q 2025). The increase in margin was primarily driven by lower expenses. New Risk • Feb 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risk Market cap is less than US$100m (₹2.12b market cap, or US$23.4m). Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹129, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 17% over the past year. 공시 • Feb 06
Quest Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026 Quest Laboratories Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Dec 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹1.60b market cap, or US$17.8m). Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹109, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.1% over the past year. 공시 • Nov 13
Quest Laboratories Limited to Report First Half, 2026 Results on Nov 13, 2025 Quest Laboratories Limited announced that they will report first half, 2026 results on Nov 13, 2025 공시 • Sep 04
Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025 Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025, at 12:30 Indian Standard Time. Reported Earnings • Jul 26
First quarter 2026 earnings released: EPS: ₹2.50 (vs ₹0.90 in 1Q 2025) First quarter 2026 results: EPS: ₹2.50 (up from ₹0.90 in 1Q 2025). Revenue: ₹231.8m (up 52% from 1Q 2025). Net income: ₹41.0m (up 178% from 1Q 2025). Profit margin: 18% (up from 9.7% in 1Q 2025). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹108, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 25% over the past year. New Risk • Jun 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.54b market cap, or US$18.0m). New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.43b market cap, or US$16.8m). New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₹1.71b market cap, or US$20.0m). Valuation Update With 7 Day Price Move • May 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹83.75, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year. Board Change • May 14
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹115, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Board Change • Mar 06
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹150, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Recent Insider Transactions • Jan 21
Chairman & MD recently bought ₹1.2m worth of stock On the 15th of January, Anil Sabarwal bought around 10k shares on-market at roughly ₹130 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹4.2m. Anil has been a buyer over the last 12 months, purchasing a net total of ₹6.7m worth in shares. Recent Insider Transactions • Jan 07
Chairman & MD recently bought ₹4.2m worth of stock On the 2nd of January, Anil Sabarwal bought around 34k shares on-market at roughly ₹125 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anil's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹128, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Reported Earnings • Nov 16
First half 2025 earnings released: EPS: ₹4.89 (vs ₹4.42 in 1H 2024) First half 2025 results: EPS: ₹4.89 (up from ₹4.42 in 1H 2024). Revenue: ₹434.6m (up 6.0% from 1H 2024). Net income: ₹80.1m (up 46% from 1H 2024). Profit margin: 18% (up from 13% in 1H 2024). Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹91.50, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Board Change • Sep 17
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Sep 06
Quest Laboratories Limited Appoints Executive Directors Quest Laboratories Limited at the AGM held on September 4, 2024 approved the regularisation of additional director Mr. Vinayak Sabarwal and Mr. Umendra Singh by appointing them as Executive Directors of the Company. 공시 • Aug 12
Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024 Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024, at 16:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹128, the stock trades at a trailing P/E ratio of 41.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.